Research programme:antisense oligonucleotide therapeutics - Roche
Alternative Names: Lymphatic Targeting Milk Exosomes - PureTech HealthLatest Information Update: 28 Aug 2022
At a glance
- Originator Roche
- Class Antisense oligonucleotides; Exosome therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified